Welcome to our dedicated page for Brainstorm Cell Therapeutics I SEC filings (Ticker: BCLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BrainStorm Cell Therapeutics Inc.'s SEC filings document a Delaware biotechnology issuer developing NurOwn® autologous MSC-NTF cells for neurodegenerative diseases. Recent Form 8-K reports cover financial results, material definitive agreements, securities purchase transactions, promissory notes, private placements and related capital-structure terms.
The filing record also documents BCLI common stock trading status, including Nasdaq removal through Form 25 and subsequent OTCQB Venture Market security disclosures. Governance filings include annual meeting matters, amendments to the 2014 Stock Incentive Plan and 2014 Global Share Option Plan, and capital-structure disclosures tied to equity and convertible-note financing.
Lebovits Chaim reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics President & CEO Chaim Lebovits reported an award of 1,800,000 shares of common stock in the form of restricted stock units under the company’s equity plan. The RSUs vest 50% on the February 26, 2026 grant date and 50% on the six‑month anniversary, contingent on his continued employment. Following this compensation grant, he holds 2,000,960 shares of common stock directly.
Yablonka Uri reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics executive Uri Yablonka received a grant of 150,000 shares of common stock in the form of restricted stock units. According to the award terms, 50% of the RSUs vest on the grant date and the remaining 50% vest six months later, contingent on continued employment. Following this compensation grant, Yablonka holds 218,464 shares directly.
Patlis Alla reported acquisition or exercise transactions in this Form 4 filing.
Brainstorm Cell Therapeutics Inc. reported that officer Alla Patlis received a grant of 100,000 shares of Common Stock in the form of restricted stock units (RSUs) at no cash cost per share. Following this award, Patlis directly holds 144,349 shares.
According to the terms, 50% of the RSU award vests on the grant date and the remaining 50% vests on the six‑month anniversary of the grant, as long as Patlis remains employed by the company through each vesting date. This filing reflects a compensation-related equity grant rather than an open‑market share purchase or sale.
FRENKEL JACOB A reported acquisition or exercise transactions in this Form 4 filing.
BrainStorm Cell Therapeutics director Jacob A. Frenkel received a grant of 200,000 shares of Common Stock in the form of restricted stock units. The award was made at a stated price of $0.00 per share as stock-based compensation, rather than an open-market purchase.
According to the grant terms, 50% of the RSUs vest on the grant date and the remaining 50% vest on the six-month anniversary of that date, if he remains employed by the company. After this award, Frenkel directly holds 243,777 shares of the company’s stock.
ARBEL IRIT reported acquisition or exercise transactions in this Form 4 filing.
Brainstorm Cell Therapeutics director Irit Arbel received an equity award of 120,000 shares of Common Stock in the form of restricted stock units. The grant was made on February 26, 2026 at a stated price of $0.00 per share, indicating it is compensation rather than an open-market purchase.
The RSUs were awarded under the company’s 2014 Global Share Option Plan. According to the terms, 50% of the RSUs vest on the grant date and the remaining 50% vest on the six‑month anniversary of the grant date, as long as Arbel remains employed by the company through each vesting date. After this award, Arbel’s reported direct holdings total 161,054 shares of Common Stock.
Brainstorm Cell Therapeutics Inc. expanded its Board of Directors from seven to eight members and appointed Peter Pitts as a director effective May 25, 2026, to serve until the company’s 2026 Annual Meeting of Stockholders and until his successor is elected and qualified.
Pitts, age 67, brings over 30 years of health care public policy experience, including prior service as Associate Commissioner of the U.S. Food & Drug Administration and President of the Center for Medicine in the Public Interest. Upon appointment, he received an option to purchase up to 150,000 shares of common stock, with half vesting immediately and half on the six-month anniversary of issuance. The Board determined he is independent under applicable SEC rules, and the company plans to enter into a standard director indemnification agreement with him.
Bairu Menghisteab reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Menghisteab Bairu received a grant of stock options to buy 150,000 shares of common stock at $0.70 per share. These options, granted under the company’s 2014 Stock Incentive Plan, expire on February 26, 2036.
The award vests over a short schedule: 50% of the options vest on the grant date and the remaining 50% vest on the six-month anniversary, as long as Bairu remains employed by the company through each vesting date. Following this grant, Bairu holds 150,000 stock options directly.
BrainStorm Cell Therapeutics director Anthony J. Polverino received a grant of stock options to acquire 150,000 shares of common stock at an exercise price of $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan and are a form of equity compensation.
The options vest in two equal parts: 50% vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant, provided he remains employed through each vesting date. All 150,000 options are scheduled to expire on February 26, 2036, giving a long-dated incentive tied to the company’s share performance.
HARTOUNIAN HARTOUN reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Hartoun Hartoun received a grant of stock options to buy 225,000 shares of common stock at $0.70 per share. These options were granted under the company’s 2014 Stock Incentive Plan and expire on February 26, 2036.
The award vests over a short period: 50% of the options vest on the grant date and the remaining 50% vest on the six‑month anniversary, as long as Hartoun remains employed through each vesting date. After this grant, he holds 225,000 stock options directly.
Lindborg Stacy reported acquisition or exercise transactions in this Form 4 filing.
BRAINSTORM CELL THERAPEUTICS INC. director Stacy Lindborg received a grant of stock options to buy 150,000 shares of common stock at $0.70 per share. All 150,000 options were outstanding after the grant.
The options were granted under the company’s 2014 Stock Incentive Plan. According to the terms, 50% of the award vests on the grant date and the remaining 50% vests on the six-month anniversary of the grant date, provided she remains employed through each vesting date. The options expire on February 26, 2036, giving a long-dated incentive tied to the company’s future share performance.